Allergy & Immunology
An ethical framework for global vaccine allocation
8 Sep, 2020 | 01:24h | UTCAn ethical framework for global vaccine allocation – Science
Commentary: Who should get the COVID-19 vaccine first? – University of Pennsylvania School of Medicine
Commentaries on Twitter
How would #COVID19 vaccines be distributed fairly across the globe once they are made available? Prominent philosophers and bioethicists outline the "Fair Priority Model", a 3-phase plan for vaccine distribution in @ScienceMagazine. https://t.co/1gdErzkRRh
— Stanford Ethics (@StanfordEthics) September 7, 2020
A new, three-phase plan for vaccine distribution for #COVID19—called the Fair Priority Model—is “the best embodiment of the ethical values of limiting harms…and recognizing equal concern for all people,” argues this #SciMagPolicyForum. Learn more: https://t.co/WKMvqKgDjl
— Science Magazine (@ScienceMagazine) September 7, 2020
Evolution of the COVID-19 vaccine development landscape
8 Sep, 2020 | 01:18h | UTCEvolution of the COVID-19 vaccine development landscape – Nature Reviews Drug Discovery
COVID-19 is, in the end, an endothelial disease
8 Sep, 2020 | 01:11h | UTCCOVID-19 is, in the end, an endothelial disease – European Heart Journal
Commentary on Twitter
COVID as an infectious disease of the “endothelium”, the lining of blood vessels, transmitted pre-sympyomatically. Explains the sepsis syndrome; explains the clotting/bleeding; explains the kidney failure.
What a nasty, nasty disease.https://t.co/5hlfL5Iik9
— David Fisman (@DFisman) September 7, 2020
Post-COVID syndrome severely damages children’s hearts; ‘immense inflammation’ causing cardiac blood vessel dilation
6 Sep, 2020 | 22:03h | UTCOriginal Study: Multisystem inflammatory syndrome in children: A systematic review – EClinicalMedicine
Commentary on Twitter
#COVID19 Multisystem inflammatory syndrome in children: A systematic review
An abnormal echocardiograph was observed in 314 of 581 patients (54·0%) with depressed ejection fraction (45·1%, n = 262 of 581) comprising the most common aberrancy.https://t.co/JqgETbH3DL pic.twitter.com/GqYtvGy0oP
— EPIDATUM (@epidatum) September 5, 2020
Does the COVID-19 cytokine storm exist?
6 Sep, 2020 | 21:55h | UTCDoes the COVID-19 cytokine storm exist? – Radboud University Medical Center
Original Study: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions – JAMA
Commentary on Twitter
Study suggests #COVID19 may not be characterized by cytokine storm. Whether anticytokine therapies will benefit patients with COVID-19 remains to be determined https://t.co/alyFUwCYRC
— JAMA (@JAMA_current) September 4, 2020
Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
6 Sep, 2020 | 21:44h | UTC
Immunological considerations for COVID-19 vaccine strategies
6 Sep, 2020 | 21:47h | UTCImmunological considerations for COVID-19 vaccine strategies – Nature Reviews Immunology
Commentary on Twitter
NEW #Review: 'Immunological considerations for COVID-19 vaccine strategies'
All you need to know about the #Covid19 vaccines in preclinical and clinical developmenthttps://t.co/AImMP6fLr0
FREE to access@MacImmunology pic.twitter.com/J1ycBsgJ3c— Nature Rev Immunol (@NatRevImmunol) September 5, 2020
Russian coronavirus vaccine results have been published
6 Sep, 2020 | 21:48h | UTCCommentaries: COVID-19 vaccines: early success and remaining challenges – The Lancet AND The Russian vaccine for COVID-19 – The Lancet Respiratory Medicine AND Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine – News Medical / The Lancet AND Russian coronavirus vaccine results have been published – here’s what they reveal – The Conversation
Commentary on Twitter
NEW—Preliminary results from Russian trials find that #COVID19 vaccine candidates led to no serious adverse events and elicit antibody response https://t.co/jGUwQa8oNd
Thread (1/8) pic.twitter.com/NWBpWDvUK3
— The Lancet (@TheLancet) September 4, 2020
Attitudes toward a potential SARS-CoV-2 vaccine: A survey of U.S. adults
6 Sep, 2020 | 21:45h | UTC
Editorial: Are we underestimating seroprevalence of SARS-CoV-2?
4 Sep, 2020 | 02:17h | UTCAre we underestimating seroprevalence of SARS-CoV-2? – The BMJ
Commentary: Are antibody tests underestimating the spread of COVID-19? – St. George’s University of London
Case report: Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection
4 Sep, 2020 | 02:10h | UTCCommentary: Can COVID-19 cause diabetes? – MedicalXpress
Commentary on Twitter
https://twitter.com/nresearchnews/status/1301179637704331265
COVID-19 and mRNA vaccines—first large test for a new approach
4 Sep, 2020 | 02:08h | UTCCOVID-19 and mRNA Vaccines—First Large Test for a New Approach – JAMA
Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic
4 Sep, 2020 | 02:06h | UTC
Coalition Covid-19 Brazil – Randomized trial: Dexamethasone improves outcomes in patients with Acute Respiratory Distress Syndrome and COVID-19
3 Sep, 2020 | 11:24h | UTCEditorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic
Related studies: Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial – JAMA AND Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA
Commentary: Inexpensive Steroids Can Save Lives Of Seriously Ill COVID-19 Patients – NPR
Commentary on Twitter
In this RCT, IV #dexamethasone increased the number of ventilator-free days by day 28 vs standard care alone among patients with #COVID19 and moderate or severe ARDS https://t.co/RA9G6LVRlz @ICURevisited @FlaviaSepsis @israelmaia16
— JAMA (@JAMA_current) September 2, 2020
Meta-analysis: Corticosteroids for critically ill patients with COVID-19
3 Sep, 2020 | 11:23h | UTCEditorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic
Commentaries: Analysis of seven trials finds that corticosteroids reduce risk of death by 20 per cent in critically ill COVID-19 patients – University of Bristol AND Multiple studies confirm steroids can fight severe COVID-19 – MedicalXpress
Commentary on Twitter
1/8 Corticosteroids and COVID19
*Three* RCTs and a new @WHO meta-analysis add to #RECOVERY trial data that corticosteroids reduce mortality in critically ill #COVID19 patientshttps://t.co/H8c46Y5DTm— JAMA (@JAMA_current) September 2, 2020
[Preprint] Randomized trial: Tocilizumab does not improve clinical status or mortality in hospitalized patients with COVID-19 pneumonia
3 Sep, 2020 | 11:19h | UTCTocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Covid-19: Study found those younger than 40 had an infection fatality ratio (IFR) of 0.01%; those 60 or older had an IFR of 1.71%
3 Sep, 2020 | 11:18h | UTC
Commentary on Twitter
Age, sex, race affect death risk from #COVID-19. @FSPH_IUPUI study found those younger than 40 had fatality rate of 0.01%; those 60 or older 1.71%—2.5 times greater than #flu https://t.co/oT4BCVbVxe. @jblackburn_phd @aaronecarroll pic.twitter.com/wE6Ti0EG6E
— Annals of Int Med (@AnnalsofIM) September 2, 2020
Humoral immune response to SARS-CoV-2 in Iceland
2 Sep, 2020 | 09:57h | UTCHumoral Immune Response to SARS-CoV-2 in Iceland – New England Journal of Medicine
Editorial: The Power of Antibody-Based Surveillance
Commentary on Twitter
I would never have guessed that IFR would become one of the most controversial topics of 2020
The IFR in today's @NEJM publication of the Iceland experience was 0.3% https://t.co/bkub1TcazK
The IFR in the preprint meta-analysis by satan was 0.27%
🤷♂️ pic.twitter.com/arz3cCKRvA— Vinay Prasad MD MPH (@VPrasadMDMPH) September 1, 2020
Cases of SARS-CoV-2 reinfection highlight the limitations — and the mysteries — of our immune system
1 Sep, 2020 | 06:18h | UTC
Asthma in COVID-19 hospitalizations: An overestimated risk factor?
1 Sep, 2020 | 06:22h | UTC
Commentary on Twitter
https://twitter.com/holguinf01/status/1300505812473843713
Scientists are reporting several cases of Covid-19 reinfection — but the implications are complicated
1 Sep, 2020 | 06:20h | UTC
Perspective: COVID-19 vaccine trials should seek worthwhile efficacy
31 Aug, 2020 | 01:45h | UTCCOVID-19 vaccine trials should seek worthwhile efficacy – The Lancet
Commentary: Covid vaccine rush could make pandemic worse, say scientists – The Guardian
Commentary on Twitter
"Although efficacy far greater than 50% would be better, efficacy of about 50% would represent substantial progress"
Philip Krause et al for the @WHO Solidarity Vaccines Trial Expert Group on why #COVID19 vaccine trials should seek worthwhile efficacy https://t.co/2VWas8YU7L pic.twitter.com/RjbeZkeAE0
— The Lancet (@TheLancet) August 28, 2020
Perspective: We’ve got a Coronavirus vaccine update for you
28 Aug, 2020 | 08:43h | UTCWe’ve Got a Coronavirus Vaccine Update for You – Self
Systematic Review: Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection
27 Aug, 2020 | 09:55h | UTC
Commentary on Twitter (Thread – Click for more)
We have published our next Cochrane review of Covid-19 tests:
Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection – Dinnes, J – 2020 | Cochrane Library https://t.co/EhD0onSgH0
— Jon Deeks FMedSci (@deeksj) August 26, 2020
Sex differences in immune responses that underlie COVID-19 disease outcomes
27 Aug, 2020 | 09:53h | UTCSex differences in immune responses that underlie COVID-19 disease outcomes – Nature
Commentaries: Sex Differences in COVID-19 Immune Responses Affect Patient Outcomes – Yale News AND Expert reaction to a study looking at sex differences in the immune response to SARS-CoV-2 – Science Media Centre AND Women may mount stronger COVID-19 immune response – MedicalXpress


